Retapamulin (Standard)

Retapamulin (Standard) is the analytical standard of Retapamulin. This product is intended for research and analytical applications. Retapamulin (SB-275833) is a topical antibiotic that binds Staphylococcus aureus and E. coli ribosomes with a Kd of 3 nM. Retapamulin can be used in researches of atopic dermatitis and prostate cancer[1][2][8].

Product Specifications

CAS Number

[224452-66-8]

Product Name Alternative

SB-275833 (Standard)

UNSPSC

12352005

Target

Antibiotic; Bacterial; Reference Standards

Related Pathways

Anti-infection; Others

Field of Research

Cancer; Infection

Smiles

C[C@@H]1[C@]23[C@](C(CC3)=O)([H])[C@]([C@H](OC(CS[C@@H]4C[C@@H]5N(C)[C@@H](CC5)C4)=O)C[C@](C=C)(C)[C@H]1O)([C@H](C)CC2)C

Molecular Formula

C30H47NO4S

Molecular Weight

517.76

References & Citations

[1]Kircik LH. Efficacy and tolerability of retapamulin 1% ointment for the treatment of infected atopic dermatitis: a pilot study. J Drugs Dermatol. 2012 Jul;11 (7) :858-60. |[2]Yan K, et al. Biochemical characterization of the interactions of the novel pleuromutilin derivative retapamulin with bacterial ribosomes. Antimicrob Agents Chemother. 2006 Nov;50 (11) :3875-81.|[3]Candel FJ, et al. In vitro activity of retapamulin against linezolid and methicillin-resistant Staphylococcus aureus isolates. Rev Esp Quimioter. 2011 Sep;24 (3) :127-30.|[4]Pérez-Trallero E, et al. In vitro activities of retapamulin and 16 other antimicrobial agents against recently obtained Streptococcus pyogenes isolates. Antimicrob Agents Chemother. 2011 May;55 (5) :2406-8. |[5]Jones RN, et al. Activity of retapamulin (SB-275833), a novel pleuromutilin, against selected resistant gram-positive cocci. Antimicrob Agents Chemother. 2006 Jul;50 (7) :2583-6. |[6]Champney WS, et al. Retapamulin inhibition of translation and 50S ribosomal subunit formation in Staphylococcus aureus cells. Antimicrob Agents Chemother. 2007 Sep;51 (9) :3385-7. |[7]Bello SO, et al. Erythromycin, retapamulin, pyridoxine, folic acid, and ivermectin inhibit cytopathic effect, papain-like protease, and MPRO enzymes of SARS-CoV-2. Front Cell Infect Microbiol. 2023 Nov 27;13:1273982.|[8]Huang Q, et al. Nitazoxanide inhibits acetylated KLF5-induced bone metastasis by modulating KLF5 function in prostate cancer. BMC Med. 2023 Feb 21;21 (1) :68. |[9]Shang R, et al. Antibacterial activity and pharmacokinetic profile of a promising antibacterial agent: 14-O-[ (4-Amino-6-hydroxy-pyrimidine-2-yl) thioacetyl] mutilin. Pharmacol Res. 2018 Mar;129:424-431. |[10]Vingsbo Lundberg C, et al. Efficacy of topical and systemic antibiotic treatment of meticillin-resistant Staphylococcus aureus in a murine superficial skin wound infection model. Int J Antimicrob Agents. 2013 Sep;42 (3) :272-5.